3.16.3. summary evidence recommendations peri-procedural antibiotic prophylaxis. summary evidencelethe outcome clinical uti reported four eleven rcts benefit found antibiotic prophylaxis vs. placebo patients following filling voiding cystometry.1ba meta-analysis five trials moderate quality showed benefit using antibiotic prophylaxis reduction symptomatic uti patients undergoing cystoscopy. however, benefit seen two trials low risk bias used meta-analysis.1atwo meta-analyses found benefit antibiotic prophylaxis following eswl terms reducing rate post-procedural fever bacteriuria trial-defined infection patients without bacteriuria.1atwo meta-analyses found evidence benefit antibiotic prophylaxis prior ureteroscopy reducing rate clinical uti; however, rate bacteriuria reduced.1aa meta-analysis five rcts demonstrated moderate level evidence antibiotic prophylaxis associated statistically significant reduction risk post-procedural uti following pnl.1atwo rcts concluded single dose suitable agent adequate prophylaxis clinical infection pnl.1ba systematic review 39 rcts concluded antibiotic prophylaxis reduced rate infectious complications men undergoing turp.1ba systematic review two rcts found benefit antibiotic prophylaxis patients undergoing turb.1ba meta-analysis eight studies including 1,596 patients showed significantly reduced infectious complications patients undergoing transperineal biopsy compared transrectal biopsy.1aa meta-analysis eight non-rcts reported comparable rates post-biopsy infections patients undergoing transperineal biopsy irrespective antibiotic prophylaxis given not.1aa meta-analysis eleven rcts including 2,237 men showed use rectal povidone-iodine preparation transrectal biopsy, addition antimicrobial prophylaxis, resulted significantly lower rate infectious complications.1aa meta-analysis eleven studies 1,753 patients showed significantly reduced infections transrectal biopsy using antimicrobial prophylaxis compared placebo/control.1a recommendationsstrength ratingdo use antibiotic prophylaxis reduce rate symptomatic urinary infection following:urodynamics;cystoscopy;extracorporeal shockwave lithotripsy.stronguse antibiotic prophylaxis reduce rate symptomatic urinary infection following ureteroscopy.weakuse single dose antibiotic prophylaxis reduce rate clinical urinary infection following percutaneous nephrolithotomy.stronguse antibiotic prophylaxis reduce infectious complications men undergoing transurethral resection prostate.stronguse antibiotic prophylaxis reduce infectious complications high-risk patients undergoing transurethral resection bladder.weakperform prostate biopsy using transperineal approach due lower risk infectious complications.stronguse routine surgical disinfection perineal skin transperineal biopsy.stronguse rectal cleansing povidone-iodine men prior transrectal prostate biopsy.strongdo use fluoroquinolones prostate biopsy line european commission final decision emea/h/a-31/1452.stronguse either target prophylaxis based rectal swab stool culture; augmented prophylaxis (two different classes antibiotics); alternative antibiotics (e.g. fosfomycin trometamol*, cephalosporin, aminoglycoside) antibiotic prophylaxis transrectal biopsy.weak *of note indication fosfomycin trometamol prostate biopsy withdrawn germany themanufacturers submit necessary pharmacokinetic data support indication. urologists advised check local guidance relation use fosfomycin trometamol prostate biopsy. table 13: suggested regimens antimicrobial prophylaxis prior urological procedures stated section 3.14.1.4 panel decided make recommendations specific agents particular procedures, listed represent possible choices only. urologists choose specific antimicrobial based knowledge local pathogen prevalence type procedure, antibiotic susceptibility profiles virulence. procedureprophylaxis recommendedantimicrobialurodynamicsnon/acystoscopynoextracorporeal shockwave lithotripsynoureteroscopyyestrimethoprimtrimethoprim-sulphamethoxazolecephalosporin group 2 3aminopenicillin plus beta-lactamase inhibitorpercutaneous nephrolithotomyyes (single dose)transurethral resection prostateyestransurethral resection bladderyes, patients high risk suffering post-operative sepsis.transrectal prostate biopsyyes1. targeted prophylaxis - based rectal swab stool culture.2. augmented prophylaxis - two different classes antibiotics*.2. alternative antibioticsfosfomycin trometamol** (e.g. 3 g 3 g 24-48 hrs biopsy)cephalosporin (e.g. ceftriaxone 1 g i.m.; cefixime 400 mg p.o. 3 days starting 24 hrs biopsy)aminoglycoside (e.g. gentamicin3mg/kg i.v.; amikacin 15mg/kg i.m.) * note option 2 antibiotic stewardship programmes** note indication fosfomycin trometamol prostate biopsy withdrawn germany manufacturers submit necessary pharmacokinetic data support indication. urologists advised check local guidance relation use fosfomycin trometamol prostate biopsy. figure 4: prostate biopsy workflow reduce infectious complications1. two systematic reviews including non-rcts two rcts describe comparable rates post-biopsy infection patients without antibiotic prophylaxis.2. informed local antimicrobial resistance.3. banned european commission due side effects.4. contradicts principles antimicrobial stewardship.5. fosfomycin trometamol (4 rcts), cephalosporins (2 rcts), aminoglycosides (2 rcts).6. one rct comparing targeted augmented prophylaxis.7. originally introduced use alternative antibiotics case fluoroquinolone resistance.8. various schemes: fluoroquinolone plus aminoglycoside (4 rcts); fluoroquinolone plus cephalosporin (1 rct).9. significantly inferior targeted augmented prophylaxis. grade working group grades evidence. high certainty: (⊕⊕⊕⊕)very confident true effect lies close estimate effect. moderate certainty: (⊕⊕⊕○)moderately confident effect estimate: true effect likely close estimate effect, possibility substantially different. low certainty: (⊕⊕○○) confidence effect estimate limited: true effect may substantially different estimate effect. low certainty: (⊕○○○) little confidence effect estimate: true effect likely substantially different estimate effect. figure reproduced pilatz et al., permission elsevier. *of note indication fosfomycin trometamol prostate biopsy withdrawn germany manufacturers submit necessary pharmacokinetic data support indication. urologists advised check local guidance relation use fosfomycin trometamol prostate biopsy